
The study aimed to investigate whether haemodialysis (HD) affects the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of evogliptin, a dipeptidyl peptidase‐4 inhibitor. The study involved eight end-stage renal disease (ESRD) patients and eight healthy subjects. The results showed that HD did not significantly affect the PK and PD profiles of evogliptin, and no dose adjustment according to HD status is necessary. However, the mean AUClast of evogliptin was approximately 1.4-fold greater in ESRD patients than in healthy subjects.
Like
Save
Share